Free tool
FAERS Monitor: Lucentis
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 125156 or its brand name (Lucentis, Ranibizumab). Reports on generic versions are filed under their own applications.
Reports
26,326
Serious
22,469
85% of reports
Hospitalization
4,810
Death reported
5,093
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death3,801
- visual acuity reduced2,891
- off label use1,729
- visual impairment1,666
- cerebrovascular accident1,239
- drug ineffective1,210
- blindness1,047
- eye haemorrhage1,047
- vision blurred1,035
- no adverse event1,028
- eye pain961
- retinal haemorrhage801
- endophthalmitis729
- myocardial infarction690
- cataract687
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2005 | 1 |
| 2006 | 52 |
| 2007 | 563 |
| 2008 | 351 |
| 2009 | 691 |
| 2010 | 1,150 |
| 2011 | 2,457 |
| 2012 | 2,382 |
| 2013 | 2,727 |
| 2014 | 2,172 |
| 2015 | 1,268 |
| 2016 | 1,251 |
| 2017 | 2,543 |
| 2018 | 1,575 |
| 2019 | 1,288 |
| 2020 | 1,266 |
| 2021 | 1,039 |
| 2022 | 853 |
| 2023 | 748 |
| 2024 | 1,233 |
| 2025 | 458 |
| 2026 | 258 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,027,833 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| endophthalmitisSignal | 729 | 110.4 | 102.2 | 69,337 |
| retinal haemorrhageSignal | 801 | 101.1 | 94.0 | 70,396 |
| visual acuity reducedSignal | 2,891 | 76.1 | 73.4 | 195,809 |
| eye haemorrhageSignal | 1,047 | 67.9 | 63.9 | 63,616 |
| blindnessSignal | 1,047 | 21.0 | 19.8 | 19,496 |
| eye painSignal | 961 | 13.8 | 13.0 | 11,258 |
| visual impairmentSignal | 1,666 | 10.9 | 10.4 | 14,814 |
| cataractSignal | 687 | 9.3 | 8.6 | 5,045 |
| vision blurredSignal | 1,035 | 6.1 | 5.7 | 4,364 |
| cerebrovascular accidentSignal | 1,239 | 5.9 | 5.6 | 5,015 |
| no adverse eventSignal | 1,028 | 4.6 | 4.3 | 2,855 |
| deathSignal | 3,801 | 3.5 | 3.4 | 7,174 |
| myocardial infarctionSignal | 690 | 3.2 | 2.9 | 1,026 |
| off label use | 1,729 | 1.6 | 1.5 | 381 |
| drug ineffective | 1,210 | 0.7 | 0.7 | 125 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.